Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Roose, S. P. Articles by Bigger, J. T. Search for Related Content PubMed Citation Articles by Roose, S. P. Articles by Bigger, J. T., Jr.

Cardiovascular Effects of Fluoxetine in Depressed Patients With Heart Disease

OBJECTIVE: The purpose of this study was to determine the cardiovascular effects of fluoxetine in depressed patients with cardiac disease. METHOD: Twenty-seven depressed patients (26% of whom were female and whose average age was 73 years) who had congestive heart failure, conduction disease, and/or ventricular arrhythmia were studied in an open medication trial of fluoxetine, up to 60 mg/day, for 7 weeks. The main outcome measures were heart rate and rhythm measured by 24-hour ECG recordings, ejection fraction determined by radionuclide angiography, cardiac conduction intervals, and blood pressure. Baseline values were compared with those at weeks 2 and 7 of fluoxetine treatment. In 60 comparable patients, values of these same cardiovascular measures at baseline and after 3 weeks of treatment with a tricyclic antidepressant, nortriptyline, were also examined. RESULTS: Fluoxetine induced a statistically significant 6% decrease in heart rate, a 2% increase in supine systolic pressure, and a 7% increase in ejection fraction. There was no effect on cardiac conduction, ventricular arrhythmia, or orthostatic blood pressure. Overall, 4% of the fluoxetine patients had an adverse cardiovascular effect. In contrast, nortriptyline treatment caused a significant increase in heart rate and orthostatic hypotension, and 20% of the nortriptyline-treated patients had an adverse cardiovascular effect. CONCLUSIONS: In depressed patients with heart disease, fluoxetine treatment was not associated with the cardiovascular effects documented for the tricyclic antidepressants or with significant adverse cardiac events. However, limited conclusions about fluoxetine's cardiovascular effects and safety can be drawn from this study of only 27 patients monitored for 7 weeks.

This article has been cited by other articles:

				T. C.T.F. Alves, J. Rays, R. M.S. Telles, R. F. Junior, M. Wajngarten, B. W. Romano, C. Watanabe, and G. F. Busatto Effects of Antidepressant Treatment on Cognitive Performance in Elderly Subjects With Heart Failure and Comorbid Major Depression: An Exploratory Study Psychosomatics, February 1, 2007; 48(1): 22 - 30. [Abstract] [Full Text] [PDF]

				C. Salzman A 60-Year-Old Woman Who Has Felt Sad for Much of Her Life JAMA, January 18, 2006; 295(3): 318 - 323. [Full Text] [PDF]

				G Dubnov, R Fogelman, and P Merlob Prolonged QT interval in an infant of a fluoxetine treated mother Arch. Dis. Child., September 1, 2005; 90(9): 972 - 973. [Abstract] [Full Text] [PDF]

				J. K. Schulman, P. R. Muskin, and P. A. Shapiro Psychiatry and Cardiovascular Disease Focus, April 1, 2005; 3(2): 208 - 224. [Abstract] [Full Text] [PDF]

				J. A. Moffitt and A. K. Johnson Short-term fluoxetine treatment enhances baroreflex control of sympathetic nervous system activity after hindlimb unloading Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2004; 286(3): R584 - R590. [Abstract] [Full Text] [PDF]

				P. O'Brien and F. Oyebode Psychotropic medication and the heart Advan. Psychiatr. Treat., November 1, 2003; 9(6): 414 - 423. [Abstract] [Full Text] [PDF]

				V. L. Serebruany, A. H. Glassman, A. I. Malinin, C. B. Nemeroff, D. L. Musselman, L. T. van Zyl, M. S. Finkel, K. R. R. Krishnan, M. Gaffney, W. Harrison, et al. Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy Circulation, August 26, 2003; 108(8): 939 - 944. [Abstract] [Full Text] [PDF]

				L. Borowicz Jr., R. Royall, M. Grega, O. Selnes, C. Lyketsos, and G. McKhann Depression and Cardiac Morbidity 5 Years After Coronary Artery Bypass Surgery Psychosomatics, December 1, 2002; 43(6): 464 - 471. [Abstract] [Full Text] [PDF]

				D. Thomas, B. Gut, G. Wendt-Nordahl, and J. Kiehn The Antidepressant Drug Fluoxetine Is an Inhibitor of Human Ether-A-Go-Go-Related Gene (HERG) Potassium Channels J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 543 - 548. [Abstract] [Full Text] [PDF]

				W. H. Sauer, J. A. Berlin, and S. E. Kimmel Selective Serotonin Reuptake Inhibitors and Myocardial Infarction Circulation, October 16, 2001; 104(16): 1894 - 1898. [Abstract] [Full Text] [PDF]

				S. P. Roose, A. H. Glassman, and S. N. Seidman Relationship Between Depression and Other Medical Illnesses JAMA, October 10, 2001; 286(14): 1687 - 1690. [Full Text] [PDF]

				P. Varriale Fluoxetine (Prozac) as a Cause of QT Prolongation Arch Intern Med, February 26, 2001; 161(4): 612 - 612. [Full Text] [PDF]

				J. J. M. H. Strik, A. Honig, R. Lousberg, A. H. P. Lousberg, E. C. Cheriex, H. G. Tuynman-Qua, P. M. J. C. Kuijpers, H. J. J. Wellens, and H. M. Van Praag Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial Psychosom Med, December 1, 2000; 62(6): 783 - 789. [Abstract] [Full Text] [PDF]

				J. L. Januzzi Jr, T. A. Stern, R. C. Pasternak, and R. W. DeSanctis The Influence of Anxiety and Depression on Outcomes of Patients With Coronary Artery Disease Arch Intern Med, July 10, 2000; 160(13): 1913 - 1921. [Full Text] [PDF]

				F CREED The importance of depression following myocardial infarction Heart, October 1, 1999; 82(4): 406 - 408. [Full Text] [PDF]

				J. C. Nelson, J. S. Kennedy, B. G. Pollock, F. Laghrissi-Thode, M. Narayan, M. S. Nobler, D. W. Robin, I. Gergel, J. McCafferty, and S. Roose Treatment of Major Depression With Nortriptyline and Paroxetine in Patients With Ischemic Heart Disease Am J Psychiatry, July 1, 1999; 156(7): 1024 - 1028. [Abstract] [Full Text]

				Fluoxetine in Depressed Cardiac Patients Journal Watch Psychiatry, July 1, 1998; 1998(701): 19 - 19. [Full Text]

				Fluoxetine in Depressed Cardiac Patients Journal Watch (General), May 26, 1998; 1998(526): 4 - 4. [Full Text]

				S. P. Roose, F. Laghrissi-Thode, J. S. Kennedy, J. C. Nelson, J. T. Bigger Jr, B. G. Pollock, A. Gaffney, M. Narayan, M. S. Finkel, J. McCafferty, et al. Comparison of Paroxetine and Nortriptyline in Depressed Patients With Ischemic Heart Disease JAMA, January 28, 1998; 279(4): 287 - 291. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us